Table 1.
Baseline demographic clinical characteristics and laboratory data of the study population
| Characteristics | Total, n = 54 | |
|---|---|---|
| Male gender, n (%) | 36 (67) | |
| Ethnicity, n (%) | ||
| Caucasian | 31 (57) | |
| Asian | 10 (19) | |
| Hispanic | 7 (13) | |
| Hawaiian | 6 (11) | |
| Others | 3 (6) | |
| Age, years, mean ± SD | 52.5±5.8 | |
| HCV genotypes, n (%) | ||
| Genotype 1 | 30 (56) | |
| Genotype 2 | 9 (16) | |
| Genotype 3 | 15 (28) | |
| Weight, kilograms, mean ± SD | 85.0± 19.1 | |
| BMI, kilograms/m2, mean ± SD | 28.2±5.5 | |
| Baseline HCV RNA (x 106 IU/mL ± SD) | 6.45±13.4 | |
| HCV RNA > 600,000 IU/mL, n (%) | 47 (87) | |
| ALT >90 U/L, n (%) | 45 (83) | |
| Total bilirubin, mg/dlL, mean ± SD | 1.0±0.5 | |
| Serum albumin, g/dl, mean ± SD | 3.9±0.3 | |
| Liver biopsy results; | n = 38 | |
| Knodell score, mean ± SD | 8.0 ± 3.2 | |
| Minimal inflammation (≤4), n (%) | 4 (11) | |
| Mild inflammation (5-8), n (%) | 18 (47) | |
| Moderate inflammation (9-12), n (%) | 14 (37) | |
| Marked inflammation (≥13), n (%) | 2 (5) | |
| Risk factors for acquiring HCV infection, n (%) | ||
| Injection drug use | 38 (70) | |
| Tattooing | 41 (76) | |
| Sexual partners with HCV infection | 10 (19) | |
| Blood transfusion | 5 (9) | |
| History of cocaine use, n (%) | 22 (41) | |
| History of alcohol abuse, n (%) | 22 (41) | |
| History of methamphetamine use, n (%) | 2 (4) | |
| HIV co infection, n (%) | 3 (6) | |
| Underlying psychiatric disorders (depression, bipolar disorder, schizophrenia and anxiety), n (%) | 19 (35) | |
| Underlying medical conditions (diabetes mellitus, hypertension, others), n (%) | 28 (52) | |
Abbreviations: ALT = alanine transminase; BMI = body mass index; HCV = hepatitis C virus; HIV = human immunodeficiency virus; RNA = ribonucleic acid; SD = standard deviation.